Clinical trials: Renal Insufficiency
Renal Failure, End Stage Renal Disease
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
The main purpose of this study is to compare the Human Acellular Vessel (HAV) with arteriovenous fistula (AVF) when used for hemodialysis access
- Conditions
- Renal Failure, End Stage Renal Disease, Hemodialysis, Vascular Access
- Trial name
- NCT03183245
- Testing
- Human Acellular Vessel (HAV), Arteriovenous fistula (AVF), Hemodialysis
- Where
- 31 sites in United States
- Volunteers
- 242 people
- Sponsor
- Humacyte, Inc.
Heart Failure, Congestive
FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.
The purpose of this study is to assess the safety and tolerability of two doses of nesiritide (a recombinant form of the natural human peptide normally secreted by the heart in response to heart failure) when administered…
- Trial name
- NCT00270361
- Testing
- nesiritide, usual long term cardiac medications
- Volunteers
- 214 people
- Sponsor
- Scios, Inc.
Type 2 Diabetes Mellitus (T2DM), Renal Insuficiency
The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal Insufficiency
The trial was designed in a single dose, open, non-randomized, multi-dose parallel control group. The study of patients were mild and moderate renal insufficiency, and matched healthy subjects.
- Trial name
- RI (NCT06883656)
- Testing
- SAL067
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Anemia of Chronic Kidney Disease
Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease
Phase III, multicenter, randomized, open, controlled clinical trial. A study designed as phase III, in 120 patients with chronic renal failure in the pre-dialysis stage, evaluate efficacy and safety of Hemax PFS® (PFS: prefilled…
- Trial name
- NCT04036253
- Testing
- Erythropoietin alfa
- Where
- 11 sites in Argentina, Paraguay
- Volunteers
- 43 people
- Sponsor
- Bio Sidus SA
Renal Impairment
A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment
This is an open-label, single-dose study to evaluate the pharmacokinetics and safety of DBPR108 in subjects with mild, moderate, severe renal impairment and subjects with kidney failure compared to the matched control subjects…
- Trial name
- NCT04859439
- Testing
- DBPR108 tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Type 2 Diabetes Mellitus
A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)
The purpose of this study is to evaluate the efficacy and safety of omarigliptin in participants with type 2 diabetes mellitus and moderate or severe chronic renal insufficiency or end stage renal disease on dialysis with…
- Trial name
- NCT01698775
- Testing
- Omarigliptin, Glipizide, Insulin
- Volunteers
- 213 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Impairment
A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function
The primary purpose of this study is to assess the effect of renal impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe renal…
- Trial name
- NCT05940402
- Testing
- Emraclidine
- Where
- 5 sites in United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- AbbVie
Renal Impairment
A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants
The purpose of this study is to evaluate the pharmacokinetic of a single oral dose of JNJ-42847922 in adult participants with renal impairment compared with healthy participants with normal renal function.
- Trial name
- NCT04616677
- Testing
- JNJ-42847922
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Renal Insufficiency, Healthy
Clinical Pharmacology of FYU-981 (Subjects With Renal Insufficiency)
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics and safety after single oral administration of FYU-981 to subjects with renal insufficiency and with normal renal function.
- Trial name
- NCT02347046
- Testing
- FYU-981, (Oral single dosing)
- Where
- Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Fuji Yakuhin Co., Ltd.
Renal Insufficiency, Chronic
Bringing Knowledge About Chronic Kidney Disease in Brazil: Filling the Gap
This is a multicenter cross-sectional study will randomly screen kidney function in adult patients with known risk factors for chronic kidney disease (CKD) within the Brazilian general population.
- Trial name
- Filling gap (NCT07103629)
- Where
- Brazil
- Volunteers
- 8,428 people
- Sponsor
- AstraZeneca
Renal Insufficiency, Chronic, Kidney Disease, Chronic
A Study of LY2928057 in Hemodialysis Participants
This study will evaluate the safety of LY2928057 and how LY2928057 affects hemoglobin in hemodialysis participants. This study will involve multiple doses of LY2928057 given during a 6 week period either after a participant…
- Trial name
- NCT01991483
- Testing
- LY2928057
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Renal Anemia
A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin
The purpose of this study is to test the safety and efficacy of FG-2216 in the treatment of patients with renal anemia who are not receiving erythropoietin and who are not on dialysis.
- Trial name
- NCT00456053
- Testing
- FG2216
- Where
- 27 sites in United States
- Volunteers
- 145 people
- Sponsor
- Kyntra Bio
Hyperuricemia
Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects
This study aimed to evaluate the pharmacokinetics, pharmacodynamics, and safety of SHR4640 tablets in subjects with moderate renal insufficiency and healthy subjects, and to explore the relationship between renal function (e.g.…
- Trial name
- NCT05954169
- Testing
- SHR4640
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
An Open-Label Pharmacokinetics and Safety Study of Talazoparib
This trial will investigate the pharmacokinetics (PK) and safety of talazoparib in patients with advanced solid tumors and impaired renal function.
- Trial name
- NCT02997163
- Testing
- Talazoparib
- Where
- 10 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Pfizer
Chronic Kidney Disease
Phase 1a Study Assessing Safety, Tolerability, Pharmacokinetics, and Immunogenicity of PMG1016
This study is a first-in-human (FIH), randomized, double-blind, placebo-controlled study of PMG1016 in healthy adult participants.
- Trial name
- NCT07615985
- Testing
- PMG1016 Dose 1, PMG1016 Dose 2, PMG1016 Dose 3
- Where
- Australia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pulmongene Ltd.
Renal Impairment
Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function
This study will be assessing the pharmacokinetics of NKTR-118 in subjects with renal impairment compared to that in subjects with normal renal function.
- Trial name
- NCT01372826
- Testing
- NKTR118 Group1, NKTR118 Group 2, NKTR118 Group3
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Kidney Disease, Type 2 Diabetes Mellitus
An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), a long-term, progressive decrease in the kidneys' ability to work properly.
- Trial name
- FIGARO-BM (NCT05013008)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- 115 sites in United States, Australia and 19 more
- Volunteers
- 951 people
- Sponsor
- Bayer
Hepatic Insufficiency, Renal Insufficiency
A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations
The objective of this study is to evaluate the pharmacokinetic profile and safety of anaprazole sodium in adult subjects, particularly including the elderly and those with renal or hepatic impairment.
- Conditions
- Hepatic Insufficiency, Renal Insufficiency, Elderly
- Trial name
- NCT07345689
- Testing
- Anaprazole Sodium enteric-coated tablet
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Kidney Diseases
China Kidney Patient Trials Network
This is a prospective multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease in China.
- Trial name
- CKPTN (NCT05036850)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- George (Beijing) Clinical Research Co. Ltd.
Diabetes Mellitus, Type 2
Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment
The purpose of this study is to determine whether dapagliflozin is effective in the treatment of type 2 diabetes in subjects with poor blood sugar control and moderate renal impairment
- Trial name
- NCT00663260
- Testing
- Dapagliflozin
- Where
- 96 sites in United States, Argentina and 11 more
- Volunteers
- 631 people
- Sponsor
- AstraZeneca